G1 Therapeutics (NASDAQ:GTHX) Rating Lowered to Hold at Wedbush

Wedbush lowered shares of G1 Therapeutics (NASDAQ:GTHX) from a strong-buy rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. Wedbush also issued estimates for G1 Therapeutics’ Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.19) EPS, FY2026 earnings at ($0.09) EPS, FY2027 earnings at $0.16 EPS and FY2028 earnings at $0.35 EPS.

Several other research analysts have also issued reports on GTHX. HC Wainwright cut their price target on G1 Therapeutics from $9.00 to $3.00 and set a buy rating on the stock in a report on Tuesday, June 25th. Needham & Company LLC restated a hold rating on shares of G1 Therapeutics in a report on Wednesday.

G1 Therapeutics Price Performance

Shares of G1 Therapeutics stock remained flat at $7.09 during midday trading on Wednesday. The company had a trading volume of 2,130,973 shares, compared to its average volume of 1,696,443. The stock’s fifty day moving average is $3.34 and its two-hundred day moving average is $3.70. G1 Therapeutics has a one year low of $1.08 and a one year high of $7.10. The stock has a market capitalization of $370.67 million, a price-to-earnings ratio of -11.44 and a beta of 1.53. The company has a current ratio of 2.94, a quick ratio of 2.55 and a debt-to-equity ratio of 1.34.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The firm had revenue of $16.55 million during the quarter, compared to the consensus estimate of $15.88 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. As a group, sell-side analysts forecast that G1 Therapeutics will post -0.5 EPS for the current year.

Institutional Trading of G1 Therapeutics

A number of large investors have recently modified their holdings of the business. Financial Advocates Investment Management purchased a new stake in G1 Therapeutics in the fourth quarter worth approximately $39,000. Los Angeles Capital Management LLC purchased a new position in shares of G1 Therapeutics in the second quarter worth $48,000. SG Americas Securities LLC bought a new stake in G1 Therapeutics during the 1st quarter valued at $58,000. Capstone Investment Advisors LLC purchased a new stake in G1 Therapeutics during the 4th quarter valued at $76,000. Finally, Jump Financial LLC bought a new stake in G1 Therapeutics in the 4th quarter worth $105,000. Institutional investors own 24.21% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.